Drug intelligence / Profile preview

ALF602

Development stage: Preclinical
Lead developer: Allife Medical Science and Technology
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

ALF602 is an induced pluripotent stem cell (iPSC)-derived platelet therapy under development by Allife Medical Science and Technology for the treatment of thrombocytopenia. The product consists of functional platelets generated in vitro from iPSC lines, designed to serve as a scalable and standardized alternative to traditional donor-derived platelet transfusions. By supplementing or replacing a patient's deficient platelet supply, ALF602 aims to restore hemostatic function and prevent or treat bleeding episodes associated with low platelet counts. It is currently in the preclinical stage of development.

Beyond the preview

Go deeper on ALF602.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALF602.

Explore the full profile